The significant improvement in KCCQ scores with SGLT-2 inhibitors suggests that these drugs not only enhance cardiac function but also improve patients’ quality of life.[44] This may be related to the role of SGLT-2 inhibitors in reducing HF symptoms, improving exercise tolerance, and decreasing rehospitalization rates.[45] Studies have also indicated that SGLT-2 inhibitors may indirectly enhance patients’ quality of life by improving their psychological state, such as by reducing anxiety and depression.[46]. This evidence concerns the gene SLC5A2 and hydrops fetalis.